department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Carbidopa Oceanside · pharmadog

pharmadog
drugs
Carbidopa Oceanside

drug

patient view →

carbidopa

Marketedupdated 2mo ago

by Bausch Health Americas Inc

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 24 investigational indications.

indications

investigational

Parkinson's Disease

all catalysts(100)

approval · 100

view all 100 catalysts →

News(0)

no news has mentioned this drug yet

brand

Carbidopa Oceanside

generic

carbidopa

MOA

12.1 Mechanism of Action Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain. Levodopa Levodopa is the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa treats the symptoms of Parkinson's disease.

indication

Parkinson's Disease

phase

marketed

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

DUOPA (CARBIDOPA) — FDA approval

DUOPA (CARBIDOPA) — FDA approval

DUOPA (CARBIDOPA) — FDA approval

DUOPA (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

Data sources

openFDA · ClinicalTrials.gov

last refreshed 32m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$ORN14.89+0.54%

$ORN14.89+0.54%

$OGN13.56+0.07%

$OGN13.56+0.07%

$ORN14.89+0.54%

$OGN13.56+0.07%

$ORN14.89+0.54%

$ORN14.89+0.54%

$ORN14.89+0.54%

$ORN14.89+0.54%

$OGN13.56+0.07%

$OGN13.56+0.07%

$ORN14.89+0.54%

$ORN14.89+0.54%

$OGN13.56+0.07%

$OGN13.56+0.07%

$ORN14.89+0.54%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$OGN13.56+0.07%

$ORN14.89+0.54%

$ORN14.89+0.54%

$ABBV254.76-2.42%

$ABBV254.76-2.42%

$ABBV254.76-2.42%

$ORN14.89+0.54%

$ABBV254.76-2.42%

$ORN14.89+0.54%

$ORN14.89+0.54%

Trials studying carbidopa

phase3A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuationscompletedn=165
phase1A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participantsrecruitingn=12
—Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Diseaseactive not recruitingn=100
phase2Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuationscompletedn=61
phase1A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patientscompletedn=8
phase2Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopacompletedn=20
phase1A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjectscompletedn=35
phase2Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgiacompletedn=122

more trials →